Disclosure NewswireTMiCrowdNewswire - Oct 14, 2016
Richmond, British Columbia – Liberty Biopharma Inc. (“Liberty” or “Company”) is pleased to announce the initial application, in three separate human cases, of its regenerative microisolate from autologous adipose tissue (“RMAAT”) for intravenous (IV) infusion therapy of autoimmune and other medical applications.
For each individual case, approximately 60 million refined RMAAT cells were isolated and gravity infused with 250ml of standard intravenous solution over a 90-minute period.
The procedures were conducted with informed patient consent and the patients reported to the Company that there were no adverse events from the therapy.
Liberty is presenting and documenting these initial cases – in collaboration with medical professionals and researchers — for further review, analysis and clinical application.
The Company invites researchers and clinical specialists interested in autologous adipose stem cell IV infusion therapy for autoimmune and therapeutic medical applications to contact Liberty Biopharma Inc.
About Liberty Biopharma Inc.
Liberty is a wholly-owned subsidiary of Avapecia Life Sciences Corp. (CSE: VVS) (“Avapecia”) responsible for the worldwide marketing of the Avagenesis Corp. (TSXV: VVA) (“Avagenesis”) and Avapecia standardized adipose stem cell therapy isolation and enrichment platform. Any cash flow streams from activities will be accounted for and allocated to whichever of Avagenesis or Avapecia holds the intellectual property for the specific medical indication, condition and market from which the cash flow is derived.
Neither the TSX Venture Exchange or the Canadian Securities Exchange nor their respective regulation services providers (as that term is defined in their respective policies) accepts responsibility for the adequacy or accuracy of this press release.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “likely”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that the Company may not successfully transition to a clinical stage company and successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Readers are cautioned that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
For further information, please contact:
Liberty Biopharma Inc.
Alan Tam, CPA, CA
Chief Financial Officer
Telephone: (604) 604-377-7575